Trial
NCT00585416
Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Wisconsin, Madison
Collaborators
Progen Pharmaceuticals
Condition
Prostate Cancer
Intervention
CGC-11047
Why stopped
Further evaluation of phase I dosing
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-10-02